{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:16Z","timestamp":1791994576502,"version":"4.4.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as linagliptin, have been implicated in inducing bullous pemphigoid (BP) in elderly diabetic patients. Stapokibart is a humanized monoclonal antibody targeting interleukin-4 receptor subunit alpha (IL-4R\u03b1), primarily used for atopic dermatitis, with no prior reports of its application in BP. This article describes a case of DPP-4 inhibitor-induced bullous pemphigoid treated with Stapokibart. Following Stapokibart therapy, the patient exhibited complete resolution of skin lesions, significant improvement in quality of life, and no adverse reactions. This case suggests that Stapokibart may be an effective treatment for bullous pemphigoid induced by DPP-4 inhibitors.<\/jats:p>","DOI":"10.3389\/fmed.2026.1755336","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:10:17Z","timestamp":1774019417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Man","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shue","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]},{"name":"Department of Emergency, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]},{"name":"Department of Dermatology, Deyang Hospital Affiliated to Hospital of Chengdu University of Traditional Chinese Medicine","place":["Deyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Emergency, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1697048","DOI":"10.3389\/fmed.2025.1697048","article-title":"Case report: dupilumab in difficult-to-treat bullous pemphigoid at the university hospital Schleswig-Holstein, campus Kiel","volume":"12","author":"Mehrjerdian","year":"2026","journal-title":"Front Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"8832643","DOI":"10.1155\/2020\/8832643","article-title":"Clinical features and outcomes of dipeptidyl Peptidase-4 inhibitor-associated bullous pemphigoid (DPP4i-associated BP) in Thai patients","volume":"2020","author":"Thewjitcharoen","year":"2020","journal-title":"Case Rep Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e3391","DOI":"10.1002\/dmrr.3391","article-title":"Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Yang","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in bullous pemphigoid treatment: a comprehensive pipeline update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.humimm.2014.01.005","article-title":"<article-title update=\"added\">IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice","volume":"75","author":"Feldrihan","year":"2014","journal-title":"Hum Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1080\/07853890.2023.2188487","article-title":"Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid","volume":"55","author":"Chen","year":"2023","journal-title":"Ann Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1196946","DOI":"10.3389\/fmed.2023.1196946","article-title":"Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches","volume":"10","author":"Toh","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998370106250610103519","article-title":"From diabetes to dermatology: the role of teneligliptin in bullous pemphigoid development","author":"Hussain","year":"2025","journal-title":"Curr Diabetes Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/25785826.2019.1619233","article-title":"Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics","volume":"42","author":"Nishie","year":"2019","journal-title":"Immunol Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1157250","DOI":"10.3389\/fimmu.2023.1157250","article-title":"Biological treatment for bullous pemphigoid","volume":"14","author":"Oren-Shabtai","year":"2023","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1050373","DOI":"10.3389\/fimmu.2022.1050373","article-title":"Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1615108","DOI":"10.3389\/fmed.2025.1615108","article-title":"Successful treatment of pityriasis lichenoides et varioliformis acuta with stapokibart: a case report","volume":"12","author":"Shi","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/1750743X.2025.2554562","article-title":"Evaluating stapokibart in the treatment of seasonal allergic rhinitis","volume":"17","author":"Wang","year":"2025","journal-title":"Immunotherapy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"110721","DOI":"10.1016\/j.isci.2024.110721","article-title":"Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of Dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"111157","DOI":"10.1016\/j.intimp.2023.111157","article-title":"Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study","volume":"125","author":"Huang","year":"2023","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1755336\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:10:17Z","timestamp":1774019417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1755336\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":16,"alternative-id":["10.3389\/fmed.2026.1755336"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1755336","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"article-number":"1755336"}}